Medical

Our study showed that patients with medical cannabis authorization have a higher risk of emergency department visits or hospitalizations for depression compared to patients with no authorization. Our results also suggest that this risk is increased among patients without prior mental health disorders at cannabis authorization. The findings emphasize the need for a careful risk-benefit assessment that takes into account this observation prior to cannabis authorization. Further longitudinal

These results indicate that legal medical marijuana, particularly when available through retail dispensaries, is associated with higher opioid mortality. The results for recreational marijuana, while less reliable, also suggest that retail sales through dispensaries are associated with greater death rates relative to the counterfactual of no legal cannabis.

But  the  lives  of  vulnerable  people  may  be  put  at  risk when  science  is  distorted  for corporate  or  ideological  ends.  As  noted,  several  USstates  responded  to the  much-hypedoriginal study of cannabis and opioid overdosesby authorizing the use of medical cannabis to treat  heroin-addicted  individuals.  Advice  that  opioid  users  should use medical  cannabis toreplace  opioid  agonist  therapies  (e.g.,  methadone,  buprenorphine) poses significant  risk because abrupt cessation of these medications dramatically increases the risks of an overdose death if users return to opioid use 

http://www.cqstatetrack.com/texis/redir?id=586a677b847&rtype=text&origin...
HB 158 - AS INTRODUCED    2017 SESSION   17-0115   01/09     HOUSE BILL 158
 AN ACT adding opioid addiction to qualifying medical conditions under therapeutic use of cannabis.
 SPONSORS: Rep. Schleien, Hills. 37; Rep. E. Edwards, Hills. 11; Rep. Fisher, Belk. 9; Rep. Zaricki, Hills. 6; Rep. Josephson, Graf. 11
 COMMITTEE: Health, Human Services and Elderly Affairs
ANALYSIS
 This bill adds opioid addiction to the qualifying medical conditions under therapeutic use of cannabis.
 Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
17-0115  01/09   STATE OF NEW HAMPSHIRE  
In the Year of Our Lord Two Thousand Seventeen   AN ACT adding opioid addiction to qualifying medical conditions under therapeutic use of cannabis.   Be it Enacted by the Senate and House of Representatives in General Court convened:
 1  Use of Cannabis for Therapeutic Purposes; Definitions.  Amend RSA 126-X:1, IX(a)(1) to read as follows:
(1)  Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C currently receiving antiviral treatment, amyotrophic lateral sclerosis, muscular dystrophy, Crohn's disease, multiple sclerosis, chronic pancreatitis, spinal cord injury or disease, traumatic brain injury, epilepsy, lupus, Parkinson's disease, Alzheimer's disease, ulcerative colitis, opioid addiction, or one or more injuries that significantly interferes with daily activities as documented by the patient's provider; an
2  Effective Date.  This act shall take effect 60 days after its passage.

Is legal 'medical' marijuana linked to high youth substance abuse rates?

Let's look at Colorado's substance abuse rates in 2011- 2012 when medical marijuana was legal but recreational pot was not, Colorado youth ages 12- 17 and 18- 25 ranked in the top percentiles for most substance abuse rates: illicit drugs, marijuana, cocaine, non-medical use of painkillers and ranked the lowest for perception of great risk of smoking marijuana.

A separate analysis of edible marijuana found that many products laced with pot, such as drinks, baked goods and candy, misrepresent the potency of THC, the active ingredient on the labels. Only 13 of 75 products tested were accurately labeled, making reads of their potency and its effects little more than a guessing game.
Celebrating the medical benefits, if any, of marijuana has been an effective ruse to win social acceptance for getting high. This was thoroughly predictable, and now it’s clear that the organized pot heads have been blowing smoke at us.

NOT A PRESCRIPTION 
He quickly glanced over my medical history, asked me some cursory questions about my wrist and noted in less than three minutes that he didn’t “see any reason why [I] shouldn’t try marijuana to help with the pain.” I had the recommendation letter in PDF form in my email inbox soon after and used the rest of my consultation time to press Dr. Zlotolow on the perceived benefits of using an app to diagnose patients.

79 different studies: they found only moderate evidence indicating that marijuana reduced nerve pain and pain from cancer. 
If a pharmaceutical company, for example, wanted to get a drug approved for a medical condition and they only submitted anecdotal data, there's absolutely no chance that that drug would be approved.

Five legal standards are:

1. Does marijuana have a known and reproducible drug chemistry?
2. Does marijuana have adequate safety studies?
3. Are there adequate and controlled studies showing marijuana’s efficacy?
4. Are marijuana’s therapeutic benefits accepted by qualified experts?
5. Are scientific data available for scrutiny?

To sustain the view that marijuana should remain in Schedule I, the prosecution team also had to show that marijuana has:

1. A high potential for abuse,
2. No currently accepted medical use in treatment in the United States, and
3. Unacceptable safety standards for its use under medical supervision.

Marijuana does possess certain medicinal properties. So does opium. But we don’t allow unscrupulous quacks to write raw opium prescriptions for anyone willing to pay $65. And if we did, would anybody be surprised that the vast majority of opium buyers were not recovering from surgery—and that many of them shared or resold some of their opium to underage users?